A Study of the Use of Combination of Anti-cholinergic and Minor Tranquilliser in the Treatment of Non-cardiac Chest Pain - a Double Blind Placebo Controlled Study
The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government.
Read our disclaimer for details.
ClinicalTrials.gov Identifier: NCT00516854
Verified July 2010 by Hospital Authority, Hong Kong. Recruitment status was: Recruiting
Non-cardiac chest pain is a common clinical problem encountered in our practice but at present, the results of treatments are unsatisfactory. The pathogenesis remains unknown but altered motility of the esophagus and psychological factors including anxiety have been implicated as important factors. Reports of the single use of anticholinergic drugs and anxiolytics have yielded conflicting results, has been demonstrated to yield marginal or of no value. However the use of the combination therapy, especially with a double blind fashion have not been reported. On that basis, we propose to use a combination of anti-cholinergic and tranquilliser for the symptomatic treatment of non-cardiac chest pain. The aim of this study is to evaluate the efficacy of combination therapy of anti-cholinergic and anxiolytic drugs in the treatment of non-cardiac chest pain.
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.
Ages Eligible for Study:
18 Years and older (Adult, Senior)
Sexes Eligible for Study:
Ambulatory patients over the age of 18
Patients who are normal endoscopically
Patients who do not have symptomatic reflux disease
Patient who have normal coronary angiogram or patient with normal exercise radionuclide scan or patient with normal persantin radionuclide scan.
Patients with history of significant cardiac, renal, pulmonary or hepatic diseases,
Patients with history of dyspepsia or peptic ulcer diseases
Patient with documented reflux diseases.
Patient on drugs that affect gastrointestinal motility in the past 2 weeks
Patients who are pregnant or lactating
Patients who are suffering from costochrondritis
Patients who are known to be sensitive to benzodiazepine or anti-cholinergic
Patients with glaucoma and benign prostatic hypertrophy